1 option
CADTH Canadian Drug Expert Committee recommendation : indication : diabetes mellitus, type 2 to improve glycemic control. Semaglutide (Ozempic -- Novo Nordisk Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Insulin.
- Hypoglycemia--Chemotherapy.
- Hypoglycemia.
- Physical Description:
- 1 online resource
- Edition:
- Final.
- Place of Publication:
- Ottawa (ON) : CADTH, 2019.
- Summary:
- The committee considered the following information prepared by the CADTH Common Drug Review (CDR): a systematic review of eight RCTs of semaglutide, a critique of the manufacturer-submitted ITCs, and a critique of the manufacturer's pharmacoeconomic evaluation. The committee also considered input from a clinical expert with experience in treating patients with diabetes, and patient group-submitted information about outcomes and issues important to patients.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.